Latest news and press releases about FibroBiologics, Inc. Common Stock (FBLG): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair.
Price
| Price | $1.43 |
| Market Cap | $3M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.16 |
| EV / EBITDA | -0.10 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -536.78% |
| Return on Invested Capital | -274.34% |
| Return on Assets | -228.77% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADTX · AIMD · APLM · ATHA · CTXR · DARE · HOTH
Explore sector: Healthcare · Biotechnology
More sections of FBLG: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks